The Acute and Chronic Effects of Fruit Polyphenols on Chronic Disease (PPF)

Overweight Clinical Trial

Official title:

A Randomized Placebo Controlled Trial to Test the Acute and Chronic Effects of Fruit Polyphenols on Postprandial Indices of Chronic Disease (PPF)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01729949
• Other study ID #: PPF 2012-073
• Status: Completed
• Phase: N/A
• Start date: December 1, 2012
• Est. completion date: June 26, 2018

Study information

• Verified date: July 2021
• Source: Clinical Nutrition Research Center, Illinois Institute of Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

1. The primary objective is to determine the effect of fruit polyphenols on postprandial lipoprotein triglyceride metabolism after consumption a standard high carbohydrate/fat breakfast meal with a beverage rich in fruit-derived polyphenols compared to energy and macro-/micro-nutrient matched control beverage (acute, Part 1).

2. Secondary objectives are: 1)to assess the effects of consuming daily for 8 weeks (chronic, Part 2) a beverage rich in fruit polyphenols compared to an energy and macro-/micro- nutrient matched control beverage on fasting glucose, insulin, lipids and markers of oxidative stress; and 2) to assess the effects of these beverages on meal-related changes in metabolic and oxidative stress measures after 8 weeks daily consumption.

Description:

The study is a single-center, double-blinded, randomized, 2-part, 2-arm, 4-sequence, crossover study that incorporates both the acute and chronic evaluations of fruit polyphenols on metabolic indices and markers of oxidative stress.

A planned sample size of 30 overweight men and women will be recruited into the study. Subjects will be required to meet several inclusion and exclusion criteria, which will be assessed through online and clinic screening mechanisms, including questionnaires, blood analysis, and anthropometric measurements. Eligible subjects will be invited to participate in the study. Subjects will begin by completing a 7-day pre-study assessment of their usual dietary intake using 3-day food diary followed by washout of dietary polyphenols. Subjects will participate in 4, 6 h postprandial study days: 2 preceding the chronic intervention and 2 after 8 weeks each of active (fruit polyphenols) and placebo beverages. Subjects will be randomized on the first day of starting the acute and chronic study phases. Subjects will be asked to limit polyphenolic containing foods and beverages for 3 days prior to each 6 h postprandial study visit as well through the chronic dietary intervention. Subjects will be provided a standardized dinner meal pack on the day before each 6 h postprandial visit.

For each 6 h postprandial study visit, subjects will arrive fasted and follow procedures published by our lab previously. This includes: pre-study evaluation for compliance (fasting, dinner consumption, limited polyphenol intake) and readiness for study visit, catheter placement by registered nurse, fasting blood sample, consumption of high fat/carbohydrate meal accompanied by 1 of the two treatment beverages (active/fruit polyphenol or placebo beverage), subsequent blood sampling from catheter [ ~1 tablespoon (12ml)] at designated time points for 6 hours. Each postprandial study visit day will last approximately 7 hours and subjects will be required to remain at the Clinical Nutrition Research Center at the Illinois Institute of Technology main campus for the duration of the visit. The visit procedures are repeated twice ~ 1 week apart to accommodate subject testing with both beverages.

After completing both acute 6 h postprandial study visits, subjects will roll over to the chronic phase of the study and receive a 2nd randomization sequence for consuming the active or the placebo beverage daily for 8 weeks. Before crossing over to the alternative treatment beverage for another 8 weeks, subjects will have a 4-week break (wash out). Subjects will be counseled for a low polyphenolic diet throughout the study to consume the assigned beverage twice per day with lunch and evening meals (except during 4-week washout).

At the end of each week 8 treatment period, subjects will come to the research center for a 6 h postprandial study visit day: all procedures are identical on each postprandial study test visit with the exception that only the placebo beverage will be consumed with the breakfast.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: June 26, 2018
• Est. primary completion date: March 20, 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Non-smoking healthy overweight or class I obesity adult men and women

• Age 40-65yr

• Weight stable

• Able to provide informed consent

• Able to comply and perform the procedures requested by the protocol.

Exclusion Criteria:

• Smokers or recent past smokers

• Men or women with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients

• Diabetes

• Fasting blood glucose concentrations >125 mg/dL

• Fasting Total Cholesterol >250 mg/dL (6.47mmol/L)

• Fasting Triglycerides >250 mg/dL (2.82 mmol/L)

• Fasting LDL cholesterol >180 mg/dL (4.66 mmol/L)

• Uncontrolled blood pressure >140 mmHg/90 mmHg

• Documented vascular disease

• Cancer other than skin (non-melanoma) in previous 5 years

• Lactating and/or pregnant

• Taking medications or dietary supplements eg., antioxidant supplements, lipid lowering medication, blood pressure lowering medications.

• Recent blood donors (within 3 months)

• Vegans

• Substance (alcohol or drug) abuser (within the last 2 years)

• Participated in a chronic feeding or medication clinical trial in the last 3 months.

• Excessive coffee and tea consumers (> 4 cups/d)

Related Conditions & MeSH terms

• Chronic Disease
• Metabolic Diseases
• Nutritional and Metabolic Disease
• Overweight

Intervention

Dietary Supplement:
• Active Treatment Beverage
Strawberry and Blackcurrent extract
• Placebo Treatment Beverage
without active components

Locations

Country	Name	City	State
United States	Clinical Nutrition Research Center	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
Clinical Nutrition Research Center, Illinois Institute of Technology	GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in plasma glucose concentrations	Changes in Plasma glucose concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, Cmax and TMax	Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h).
Other	Changes in polyphenol anthocyanin concentrations	Changes in Plasma polyphenol anthocyanin concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, Cmax and TMax	Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h).
Primary	Changes in Plasma Triglycerides Concentrations	Changes in Plasma Triglyceride concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC	Acute Postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
Secondary	Changes in Plasma Lipid and Lipoprotein panels	Changes in Lipids (panel) and lipoprotein particle size/density by nuclear magnetic resonance (NMR)	Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
Secondary	Changes in insulin concentrations	Changes in Plasma insulin concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, Cmax and TMax	Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
Secondary	Changes in LDL oxidation	Changes in Plasma OxLDL concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, and Cmax	Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
Secondary	Changes in F2-isoprostane concentrations	Changes in Plasma F2-isoprostane concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phases assessed by iAUC, total AUC, Cmax and TMax	Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)